iAnthus Capital Holdings, Inc.

What they do

iAnthus owns and operates licensed cannabis cultivation, processing, and dispensary facilities across seven U.S. states. The company cultivates cannabis, processes biomass into oils and resins, and sells branded products (e.g., GrowHealthy, Cheetah, The Vault, Black Label, MPX) through its own retail dispensaries and wholesale to third parties. It also manufactures products under white-label and licensing agreements. As of June 30, 2026, it operated 41 dispensaries and six cultivation/processing facilities.

Revenue drivers

• Retail dispensary sales — Revenue from medical and adult-use cannabis sold at 41 company-owned dispensaries; retail is the primary sales channel.
• Wholesale distribution — Distribution of branded products to over 600 dispensaries in Maryland, Massachusetts, Illinois, Pennsylvania, and New Jersey, as of December 31, 2025.
• Branded product portfolio — Sales of proprietary brands including GrowHealthy, Cheetah, The Vault, Black Label, MPX, Frutful, and Anthologie, plus white-label/licensed products.

Recent performance

Revenue for Q2 2026 was $35.3 million, up $1.8 million sequentially from Q1 2026 and up $0.2 million year-over-year. Gross margin was 45.5%, down 197 bps sequentially and 37 bps year-over-year. Net loss narrowed to $14.4 million from $18.7 million in Q2 2025. Adjusted EBITDA improved to $4.4 million from $1.9 million in Q2 2025. Annual revenue declined from $167.6 million in 2024 to $144.0 million in 2025, with a net loss of $40.2 million in 2025.

Strategy

Management emphasizes vertical integration across cultivation, processing, wholesale, and retail to control quality and margins. The company plans to complete the Warwick, New York cultivation/processing facility, adding roughly 32,000 square feet of space and increasing annual harvest capacity from 43,000 to 55,000 pounds. It continues to pursue capacity for up to ten cultivation/processing facilities and an uncapped number of Florida dispensary licenses. The company also seeks growth through M&A, though it acknowledges risks of integration and diversion of management attention.

Risks

• Federal illegality — Cannabis is a Schedule I controlled substance under U.S. federal law, and FDA approval is limited to a few synthetic or cannabis-derived drugs, creating legal and regulatory uncertainty.
• Liquidity and solvency — As of June 30, 2026, total liabilities exceeded total assets by $130.7 million, with cash of only $8.3 million and no long-term debt.
• Prior default and restructuring — The company defaulted on senior secured and convertible debentures in 2020, and the 2022 recapitalization diluted pre-restructuring shareholders to just 2.75% of the company.
• M&A execution risk — Acquisitions may fail to complete, incur costs, dilute financials, or result in impairment charges and integration challenges.

Outlook

Management did not provide forward guidance in the latest filings. The company is focused on completing the Warwick facility to expand cultivation capacity and improving profitability, as evidenced by sequential Adjusted EBITDA increases. It also secured a US$2.5 million revolving line of credit as of August 12, 2026, to support liquidity.